Adenosine triphosphate-based tumor chemosensitivity assay may predict the clinical outcomes of gastric cancer patients receiving taxane-based post-operative adjuvant chemotherapy  

作　　者：Yicong Bian Minzhou Huang Sheng Ma Linsheng Liu Fan Xia Zhiyao Chen Di Yu Chenrong Huang Liyan Miao 

机构地区：[1]Department of Clinical Pharmacology,The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215006,China [2]College of Pharmaceutical Science,Soochow University,Suzhou,Jiangsu 215000,China

出　　处：《Chinese Medical Journal》2022年第11期1383-1385,共3页中华医学杂志（英文版）

基　　金：National Key New Drug Creation Special Programs(No. 2017ZX09304-021);Science and Technology Plan of Suzhou(No. SYSD2017151)

摘　　要：To the Editor:Gastric cancer is one of the most commonly diagnosed cancers in the world.For patients with a pathological tumor-node-metastasis stage of II or III,postoperative adjuvant chemotherapy is generally required to reduce recurrence risk by controlling residual tumor cells following curative resection.[1]Although taxanes have recently shown promising activity in gastric cancer,[2,3]non-responders may incur costs and experience adverse reactions without clinical benefit,and efforts to select effective regimens for individuals are very important.The application of in vitro chemosensitivity assays as predictive markers in personalized cancer treatment has been investigated in several studies.[4]However,the heterogeneity of the gastric cancer response to taxane-based chemotherapy and the correlation between in vitro chemosensitivity and clinical outcomes remain unclear.

关 键 词：clinical CHEMOTHERAPY patients 

分 类 号：R735.2[医药卫生—肿瘤]